VettedRx

Hub Services Market Consolidation: Who Owns Whom in 2026

A map of the consolidating hub services market: the 2025-2026 mergers, private equity owners behind the major platforms, and what ownership changes mean for pharma buyers.

Published

The US hub services market has consolidated dramatically in 2025 and 2026. Most major hub vendors now belong to one of three ownership camps: drug distributors (McKesson, Cardinal Health), private-equity-backed platforms (CareMetx, CareTria, Valeris, and others), and public companies (Conduent, IQVIA). The defining deals of the past eighteen months were the Mercalis–PharmaCord merger that created Valeris in May 2025, CareMetx’s April 2026 acquisition of Cencora’s legacy Lash Group hub operations, and Peak Rock Capital’s purchase of Asembia. For pharma teams, the practical consequence is simple: the company you contracted with two years ago may have a new name, a new owner, and a new strategy today.

The deal timeline, 2025–2026

DateEvent
May 2025Mercalis (formerly TrialCard) and PharmaCord complete their merger and launch as Valeris, backed by Permira and Odyssey Investment Partners
June 2025McKesson’s CoverMyMeds acquires e-enrollment platform RxLightning and prior-authorization startup FastAuth
July 2025Frazier Healthcare Partners, owner of Knipper Health, acquires provider-facing benefit-investigation platform eBlu Solutions
August 2025Sycamore Partners closes its take-private of Walgreens Boots Alliance and splits it into five standalone companies, including Shields Health Solutions
January 2026Knipper Health rebrands as CareTria, integrating eBlu into a therapy-initiation platform
April 2026CareMetx acquires Cencora’s US patient services operations (legacy Lash Group) and TheraCom free-goods pharmacy
Mid-2026A Peak Rock Capital affiliate completes its acquisition of Asembia
July 2026A Warburg Pincus-led group agrees to acquire a controlling interest in rare-disease specialty pharmacy PANTHERx Rare — a signal of investor appetite across the adjacent specialty ecosystem

Who owns whom: the 2026 map

Vendors are grouped by ownership type and listed alphabetically within each group.

Distributor-owned hubs

  • CoverMyMeds — owned by McKesson since 2017. McKesson has folded its RxCrossroads hub operations into the CoverMyMeds brand and extended the platform with the 2025 RxLightning and FastAuth acquisitions.
  • Sonexus Access and Patient Support — Cardinal Health’s hub business, operated within its specialty solutions segment.

The most significant distributor move of 2026, however, was an exit: Cencora sold its US hub services business — the legacy Lash Group, one of the oldest names in patient services — to CareMetx. Two of the big three distributors now own hubs; the third has left the field.

Private-equity-backed platforms

  • Asembia — the founder-led specialty pharmacy services and hub company, host of the industry’s largest annual summit, acquired by an affiliate of Peak Rock Capital in 2026.
  • CareMetx — majority-owned by General Atlantic (since 2021) with The Vistria Group. The Cencora patient services acquisition makes it one of the largest hub operators in the market, serving over 155 brands post-close by the company’s count.
  • CareTria — the former Knipper Health, backed by Frazier Healthcare Partners, rebranded in January 2026 around an integrated order-to-therapy platform that includes eBlu Solutions.
  • ConnectiveRx — backed by Genstar Capital; itself a product of earlier roll-ups including PSKW, PDR, and Careform.
  • EVERSANA — backed by Water Street Healthcare Partners and JLL Partners; assembled from multiple patient services and commercialization businesses.
  • Inizio Engage — part of Inizio, backed by Clayton, Dubilier & Rice.
  • Orsini — the rare-disease pharmacy and patient services provider, backed by The Carlyle Group and Consonance Capital since 2022.
  • UBC — United BioSource, owned by Avista Capital Partners since 2018, after earlier stints under Medco and Express Scripts.
  • Valeris — the May 2025 merger of Mercalis (formerly TrialCard) and PharmaCord, backed by Permira and Odyssey Investment Partners.

Public companies

  • Conduent — NASDAQ-listed business services company with a long heritage in patient assistance program administration.
  • IQVIA Patient Services — the patient services arm of NYSE-listed IQVIA, expanded through its 2020 acquisition of AllCare Plus Pharmacy.
  • Paysign — NASDAQ-listed payments company whose pharma patient affordability business has grown into hub-adjacent services.

Venture-backed challengers

A newer cohort remains independent and venture-funded, competing on technology rather than headcount: Annexus Health, Courier Health, Infinitus Systems, Phil, and SamaCare. These companies are both potential partners and, given the pace of consolidation, plausible acquisition targets — as RxLightning and eBlu Solutions were in 2025.

Why the market is consolidating

Three forces are driving the roll-up:

  1. Automation economics. Electronic benefit verification and prior authorization reward scale and integration breadth. Buying a connected platform is faster than building one, which is why acquirers have repeatedly targeted workflow-technology companies rather than call centers.
  2. Manufacturer demand for fewer vendors. Brand teams increasingly want a single accountable partner across hub, affordability, and pharmacy services instead of stitching together point solutions. Merged platforms like Valeris and the expanded CareMetx pitch exactly that.
  3. Private equity’s healthcare services thesis. Hub services offer contracted, recurring revenue tied to specialty drug growth — an estimated $293.4 billion in US specialty dispensing in 2025, per Drug Channels Institute. That profile keeps attracting sponsors, as the roster of PE owners above shows.

What consolidation means for pharma buyers

Re-verify who you are actually contracting with. Names and legal entities changed across 2025–2026. Confirm your counterparty, your data ownership terms, and whether your contract has change-of-control protections.

Expect platform migrations. Merged vendors eventually rationalize duplicate technology stacks. If your program runs on the legacy system of an acquired company, ask directly about migration timelines and what they mean for your integrations.

Watch for concentration risk and conflicts. As platforms broaden, your hub vendor may also serve direct competitors or be owned by a company with interests elsewhere in your channel. Diligence should cover firewalls and information-handling policies, not just service levels.

Leverage the moment. Consolidating vendors are hungry to demonstrate retention and win consolidated books of business. Contract renewals during integration periods are a reasonable time to negotiate better reporting, stronger SLAs, and exit protections.

The hub market of 2026 has fewer, larger owners than the market of 2023 — but also a deeper bench of venture-backed challengers than ever. Buyers who track ownership as carefully as they track service quality will be positioned to benefit from both.

Sources